Comparative cellular analysis of motor cortex in human, marmoset and mouse

The primary motor cortex (M1) is essential for voluntary fine-motor control and is functionally conserved across mammals(1). Here, using high-throughput transcriptomic and epigenomic profiling of more than 450,000 single nuclei in humans, marmoset monkeys and mice, we demonstrate a broadly conserved cellular makeup of this region, with similarities that mirror evolutionary distance and are consistent between the transcriptome and epigenome. The core conserved molecular identities of neuronal and non-neuronal cell types allow us to generate a cross-species consensus classification of cell types, and to infer conserved properties of cell types across species. Despite the overall conservation, however, many species-dependent specializations are apparent, including differences in cell-type proportions, gene expression, DNA methylation and chromatin state. Few cell-type marker genes are conserved across species, revealing a short list of candidate genes and regulatory mechanisms that are responsible for conserved features of homologous cell types, such as the GABAergic chandelier cells. This consensus transcriptomic classification allows us to use patch-seq (a combination of whole-cell patch-clamp recordings, RNA sequencing and morphological characterization) to identify corticospinal Betz cells from layer 5 in non-human primates and humans, and to characterize their highly specialized physiology and anatomy. These findings highlight the robust molecular underpinnings of cell-type diversity in M1 across mammals, and point to the genes and regulatory pathways responsible for the functional identity of cell types and their species-specific adaptations.Cardiovascular Aspects of Radiolog

Vida útil e metabolismo de carboidratos em raízes de mandioquinha-salsa sob refrigeração e filme de PVC Shelf life and carbohydrate metabolism of arracacha roots stored under refrigeration and PVC film

O objetivo deste trabalho foi avaliar a influência da temperatura de armazenamento e do uso do filme de cloreto de polivinila (PVC) sobre a perda de matéria fresca e água, incidência de danos causados por frio e metabolismo pós-colheita dos carboidratos, em raízes tuberosas de mandioquinha-salsa (Arracacia xanthorrhiza). O filme de PVC reduziu a perda de matéria fresca e manteve o teor de água das raízes, durante o armazenamento por 60 dias a 5 e 10ºC. Os danos causados por frio foram inibidos nas raízes embaladas em filme de PCV, em ambas as temperaturas de armazenamento. As baixas temperaturas induziram o acúmulo de açúcares solúveis e a degradação de amido e, para as raízes armazenadas sem PVC, o aumento do conteúdo dos açúcares solúveis foi transiente e a taxa de degradação de amido foi superior à das raízes armazenadas com PVC.<br>The objective of this work was to evaluate the influence of the storage temperature and stretch polyvinylchloride (PVC) film on the loss of fresh weight and water, on the development of chilling injury symptoms, and on the postharvest metabolism of carbohydrates, in arracacha tuber roots (Arracacia xanthorrhiza). The PVC film reduced the fresh weight loss and kept water content in the roots during 60-day storage period at 5 and 10ºC. PVC film in both storage temperatures inhibited the development of external and internal chilling injury symptoms. The low temperatures induced the increase of soluble sugar content and decrease of starch concentration, where the increase in soluble sugar was transient in roots stored without PVC film, and the rate of starch degradation was higher compared to the roots stored with PVC

[In Press] Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Background: Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. Methods: This observational study included 453 severe asthma patients (41% male; mean age ± SD 55.7 ± 14.7 years) from two real-world drug registries: the Australian Mepolizumab Registry and the Australian Xolair Registry. The composite outcome clinical remission was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assessed at 12 months and 5-item Asthma Control Questionnaire (ACQ-5) ≤1 at 12 months. We also assessed clinical remission plus optimization (post-bronchodilator FEV1 ≥80%) or stabilization (post-bronchodilator FEV1 not greater than 5% decline from baseline) of lung function at 12 months. Sensitivity analyses explored various cut-offs of ACQ-5/FEV1 scores. The predictors of clinical remission were identified. Results: 29.3% (73/249) of AMR and 22.8% (37/162) of AXR cohort met the criteria for clinical remission. When lung function criteria were added, the remission rates were reduced to 25.2% and 19.1%, respectively. Sensitivity analyses identified that the remission rate ranged between 18.1% and 34.9% in the AMR cohort and 10.6% and 27.2% in the AXR cohort. Better lung function, lower body mass index, mild disease and absence of comorbidities such as obesity, depression and osteoporosis predicted the odds of achieving clinical remission. Conclusion: Biologic treatment with mepolizumab or omalizumab for severe asthma-induced asthma remission in a subgroup of patients. Remission on treatment may be an achievable treatment target and future studies should consider remission as an outcome measure